Presentation is loading. Please wait.

Presentation is loading. Please wait.

Experimental study of intermittent crossclamping with fibrillation and myocardial protection: Reduced injury from shorter cumulative ischemia or intrinsic.

Published byΣαπφώ Παπαγεωργίου Modified over 5 years ago

Similar presentations

Presentation on theme: "Experimental study of intermittent crossclamping with fibrillation and myocardial protection: Reduced injury from shorter cumulative ischemia or intrinsic."— Presentation transcript:

1 Experimental study of intermittent crossclamping with fibrillation and myocardial protection: Reduced injury from shorter cumulative ischemia or intrinsic protective effect?  Ryuzo Bessho, MD*, David J. Chambers, PhD  The Journal of Thoracic and Cardiovascular Surgery  Volume 120, Issue 3, Pages (September 2000) DOI: /mtc Copyright © 2000 American Association for Thoracic Surgery Terms and Conditions

2 Fig. l. Experimental perfusion protocols
Fig. l. Experimental perfusion protocols. Nine groups of hearts (n = at least 6 per group) were studied: group 1: 40 minutes of continuous global ischemia (C-GI; n = 9); group 2: a single-dose infusion of St Thomas' Hospital solution 2 (STH2) and 40 minutes of global ischemia (S-CP; n = 9); group 3: multidose infusions of STH2 (every 10 minutes) throughout 40 minutes of global ischemia (M-CP; n = 6); group 4: continuous VF throughout 40 minutes of global ischemia (C-GI+VF; n = 6); group 5: 4 × 10 minutes of global ischemia (with 10 minutes of reperfusion) (I-GI; n = 6); group 6: 4 × 10 minutes of global ischemia with intermittent STH2 (with 10 minutes of reperfusion) (I-CP; n = 6); group 7: 4 × 10 minutes of global ischemia with intermittent VF (and 10 minutes of reperfusion) (I-GI+VF; n = 6); group 8: 40 minutes of continuous VF with coronary perfusion (C-VF; n = 6); group 9: 4 × 10 minutes of VF with coronary perfusion (I-VF; n = 6). All protocols were followed by 60 minutes of reperfusion. The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /mtc ) Copyright © 2000 American Association for Thoracic Surgery Terms and Conditions

3 Fig. 2 Recovery of LVDP with reperfusion duration (minutes), expressed as a percentage of the preischemic control value. *P <.01: groups 3, 5, 6, 7, 8, and 9 versus groups 1, 2, and 4. Values are the mean of at least 6 hearts per group; error bars have been removed to improve clarity. LVDP, Left ventricular developed pressure; C-GI, continuous global ischemia group; S-CP, single-dose cardioplegic infusion group; M-CP, multidose cardioplegic infusion group; C-GI+VF, continuous global ischemia with ventricular fibrillation group; I-GI, intermittent global ischemia group; I-CP, intermittent cardioplegic infusion group; I-GI+VF, intermittent global ischemia with ventricular fibrillation group; C-VF, continuous ventricular fibrillation group; I-VF, intermittent ventricular fibrillation group. The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /mtc ) Copyright © 2000 American Association for Thoracic Surgery Terms and Conditions

4 Fig. 3 Recovery of LVDP at the end of 60 minutes of reperfusion, expressed as percentage of the preischemic control value. Values are the mean of at least 6 hearts per group ± SEM. *P <.05 vs groups 1, 2, 4, 8, and 9. LVDP, Left ventricular developed pressure; C-GI, continuous global ischemia group; S-CP, single-dose cardioplegic infusion group; M-CP, multidose cardioplegic infusion group; C-GI+VF, continuous global ischemia with ventricular fibrillation group; I-GI, intermittent global ischemia group; I-CP, intermittent cardioplegic infusion group; I-GI+VF, intermittent global ischemia with ventricular fibrillation group; C-VF, continuous ventricular fibrillation group; I-VF, intermittent ventricular fibrillation group. The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /mtc ) Copyright © 2000 American Association for Thoracic Surgery Terms and Conditions

5 Fig. 4 Changes in LVEDP during reperfusion (expressed as absolute value in millimeters of mercury). Values are the mean of at least 6 hearts per group ± SEM. LVEDP, Left ventricular end-diastolic pressure; N.S., nonsignificant; C-GI, continuous global ischemia group; S-CP, single-dose cardioplegic infusion group; M-CP, multidose cardioplegic infusion group; C-GI+VF, continuous global ischemia with ventricular fibrillation group; I-GI, intermittent global ischemia group; I-CP, intermittent cardioplegic infusion group; I-GI+VF, intermittent global ischemia with ventricular fibrillation group; C-VF, continuous ventricular fibrillation group; I-VF, intermittent ventricular fibrillation group. The Journal of Thoracic and Cardiovascular Surgery  , DOI: ( /mtc ) Copyright © 2000 American Association for Thoracic Surgery Terms and Conditions

Download ppt "Experimental study of intermittent crossclamping with fibrillation and myocardial protection: Reduced injury from shorter cumulative ischemia or intrinsic."

Similar presentations

The coronary delivery of marrow stromal cells for myocardial regeneration: Pathophysiologic and therapeutic implications Jih-Shiuan Wang, MD, Dominique.

The coronary delivery of marrow stromal cells for myocardial regeneration: Pathophysiologic and therapeutic implications Jih-Shiuan Wang, MD, Dominique.
A.Marc Gillinov, MD, Gosta Pettersson, MD, Thomas W. Rice, MD 

A.Marc Gillinov, MD, Gosta Pettersson, MD, Thomas W. Rice, MD 
Manuel J. Antunes, MD, PhD, DSc 

Manuel J. Antunes, MD, PhD, DSc 
Myocardial protection with oxygenated esmolol cardioplegia during prolonged normothermic ischemia in the rat  Ryuzo Bessho, MD, PhD, David J. Chambers,

Myocardial protection with oxygenated esmolol cardioplegia during prolonged normothermic ischemia in the rat  Ryuzo Bessho, MD, PhD, David J. Chambers,
Reduction of systolic and diastolic dysfunction by retrograde coronary sinus perfusion during off-pump coronary surgery  Manuel Castellá, MD, Gerald D.

Reduction of systolic and diastolic dysfunction by retrograde coronary sinus perfusion during off-pump coronary surgery  Manuel Castellá, MD, Gerald D.
B. Zane Atkins, MD, Scott C. Silvestry, MD, Ravi N. Samy, MD, Ashish S

B. Zane Atkins, MD, Scott C. Silvestry, MD, Ravi N. Samy, MD, Ashish S
Multigene adenoviral therapy for the attenuation of ischemia-reperfusion injury after preservation for cardiac transplantation  Haitham J. Abunasra, FRCS,

Multigene adenoviral therapy for the attenuation of ischemia-reperfusion injury after preservation for cardiac transplantation  Haitham J. Abunasra, FRCS,
Volume 104, Issue 3, Pages (September 1993)

Volume 104, Issue 3, Pages (September 1993)
Functional evaluation of human donation after cardiac death donor hearts using a continuous isolated myocardial perfusion technique: Potential for expansion.

Functional evaluation of human donation after cardiac death donor hearts using a continuous isolated myocardial perfusion technique: Potential for expansion.
Prolonged donor heart preservation with pinacidil: The role of mitochondria and the mitochondrial adenosine triphosphate–sensitive potassium channel 

Prolonged donor heart preservation with pinacidil: The role of mitochondria and the mitochondrial adenosine triphosphate–sensitive potassium channel 
Delivery of a nonpotassium modified maintenance solution to enhance myocardial protection in stressed neonatal hearts: A new approach  Michael T. Kronon,

Delivery of a nonpotassium modified maintenance solution to enhance myocardial protection in stressed neonatal hearts: A new approach  Michael T. Kronon,
Nitric oxide–generating β-adrenergic blocker nipradilol preserves postischemic cardiac function  Hitoshi Horimoto, MD, Adam E Saltman, MD, PhD, Glenn.

Nitric oxide–generating β-adrenergic blocker nipradilol preserves postischemic cardiac function  Hitoshi Horimoto, MD, Adam E Saltman, MD, PhD, Glenn.
Cytokines Link Toll-Like Receptor 4 Signaling to Cardiac Dysfunction After Global Myocardial Ischemia  John Cha, MD, Zhiping Wang, MD, Lihua Ao, BS, Ning.

Cytokines Link Toll-Like Receptor 4 Signaling to Cardiac Dysfunction After Global Myocardial Ischemia  John Cha, MD, Zhiping Wang, MD, Lihua Ao, BS, Ning.
The role of cardioplegia induction temperature and amino acid enrichment in neonatal myocardial protection  Michael T Kronon, MD, Bradley S Allen, MD,

The role of cardioplegia induction temperature and amino acid enrichment in neonatal myocardial protection  Michael T Kronon, MD, Bradley S Allen, MD,
Akihiko Ohkado, MD, Hung Cao-Danh, PhD, K. Eric Sommers, MD, Pedro J

Akihiko Ohkado, MD, Hung Cao-Danh, PhD, K. Eric Sommers, MD, Pedro J
Protective effects of dimethyl amiloride against postischemic myocardial dysfunction in rabbit hearts: Phosphorus 31—nuclear magnetic resonance measurements.

Protective effects of dimethyl amiloride against postischemic myocardial dysfunction in rabbit hearts: Phosphorus 31—nuclear magnetic resonance measurements.
Inhibition of protein kinase Cα improves myocardial β-adrenergic receptor signaling and ventricular function in a model of myocardial preservation  Karen.

Inhibition of protein kinase Cα improves myocardial β-adrenergic receptor signaling and ventricular function in a model of myocardial preservation  Karen.
Blood cardioplegia enhanced with nitric oxide donor SPM-5185 counteracts postischemic endothelial and ventricular dysfunction  Katsuhiko Nakanishi, MD,

Blood cardioplegia enhanced with nitric oxide donor SPM-5185 counteracts postischemic endothelial and ventricular dysfunction  Katsuhiko Nakanishi, MD,
Long-term myocardial preservation: effects of hyperkalemia, sodium channel, and NA+/K+/2CL- cotransport inhibition on extracellular potassium accumulation.

Long-term myocardial preservation: effects of hyperkalemia, sodium channel, and NA+/K+/2CL- cotransport inhibition on extracellular potassium accumulation.
Long-term treatment with nipradilol, a nitric oxide–releasing β-adrenergic blocker, enhances postischemic recovery and limits infarct size  Yoshihiro.

Long-term treatment with nipradilol, a nitric oxide–releasing β-adrenergic blocker, enhances postischemic recovery and limits infarct size  Yoshihiro.

Similar presentations

Ads by Google